New hope for SCA patients: expanded access to investigational drug troriluzole
NCT ID NCT06034886
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers the investigational drug troriluzole to people with spinocerebellar ataxia (SCA), a rare brain disorder that affects movement and coordination. Participants take a daily pill. The goal is to provide access to the drug while it is still being studied. Eligible patients must have a confirmed SCA diagnosis and adequate liver function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
troriluzole (also known as BHV-4157), taken as a daily pill
What this could lead to
If it works, this could help slow or manage symptoms of spinocerebellar ataxia, a rare and progressive neurological disease.
What could go wrong
This is an expanded access program, not a formal trial, so evidence is limited. The drug is still investigational and may not work for everyone. Liver function must be monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••